<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795595</url>
  </required_header>
  <id_info>
    <org_study_id>CRSP-ONC-005</org_study_id>
    <nct_id>NCT05795595</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CRISPR Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CRISPR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of&#xD;
      CTX131™ in subjects with relapsed or refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, multi-center Phase 1/2 study of CTX131 in subjects with relapsed/refractory&#xD;
      solid tumors. CTX131 is an is allogeneic CD70- directed chimeric antigen receptor (CAR) T&#xD;
      cell immunotherapy comprised of allogeneic T cells that are genetically modified ex vivo&#xD;
      using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR&#xD;
      associated protein 9) gene editing components (single guide RNA and Cas9 nuclease).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">May 2030</completion_date>
  <primary_completion_date type="Anticipated">April 2030</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 (Dose Escalation): Incidence of adverse events</measure>
    <time_frame>From CTX131 infusion up to 28 days post-infusion</time_frame>
    <description>Defined as dose-limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Cohort Expansion): Objective response rate (ORR)</measure>
    <time_frame>From CTX131 infusion up to 60 months post-infusion</time_frame>
    <description>ORR based on Independent Review Committee (IRC) assessment, defined as the proportion of subjects who have achieved a best overall response of CR or PR according to appropriate response evaluation criteria for each disease histology</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Cervical Carcinoma</condition>
  <condition>Esophageal Carcinoma</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>CTX131</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IV infusion following lymphodepleting chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTX131</intervention_name>
    <description>CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)</description>
    <arm_group_label>CTX131</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma,&#xD;
             cervical carcinoma, pancreatic adenocarcinoma, endometrial carcinoma, and malignant&#xD;
             pleural mesothelioma.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group performance status 0 or 1.&#xD;
&#xD;
          4. Adequate renal, liver, cardiac and pulmonary organ function.&#xD;
&#xD;
          5. Female subjects of childbearing potential and male subjects must agree to use&#xD;
             acceptable method(s) of contraception from enrollment through at least 12 months after&#xD;
             CTX131 infusion.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with anti-CD70 targeting agents&#xD;
&#xD;
          2. History of certain central nervous system (CNS), cardiac or pulmonary conditions.&#xD;
&#xD;
          3. Presence of uncontrolled bacterial, viral, or fungal infection.&#xD;
&#xD;
          4. Active HIV, hepatitis B virus or hepatitis C virus infection.&#xD;
&#xD;
          5. Primary immunodeficiency disorder or active autoimmune disease requiring steroids&#xD;
             and/or other immunosuppressive therapy.&#xD;
&#xD;
          6. Women who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alissa Keegan, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CRISPR Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Central Trials</last_name>
    <phone>+1 (877) 214-4634</phone>
    <email>MedicalAffairs@crisprtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>April 18, 2023</last_update_submitted>
  <last_update_submitted_qc>April 18, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR-T</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

